Shanghai Medicilon Inc (688202) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanghai Medicilon Inc (688202) has a cash flow conversion efficiency ratio of -0.010x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-17.10 Million ≈ $-2.50 Million USD) by net assets (CN¥1.74 Billion ≈ $254.07 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Shanghai Medicilon Inc for the company's overall valuation and market capitalisation.
Shanghai Medicilon Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Shanghai Medicilon Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Shanghai Medicilon Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Medicilon Inc ranked by their cash flow conversion efficiency. Explore Shanghai Medicilon Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Signify N.V.
AS:LIGHT
|
0.106x |
|
Sineng Electric Co Ltd
SHE:300827
|
-0.028x |
|
Sapiens International Corporation NV
TA:SPNS
|
0.020x |
|
INTERNET IN.JP.ADR 1 ON
F:IIJ
|
0.110x |
|
Reysas Gayrimenkul Yatirim Ortakligi AS
IS:RYGYO
|
0.012x |
|
The Navigator Company SA
LS:NVG
|
0.026x |
|
Suzhou Recodeal Interconnect System Co Ltd
SHG:688800
|
0.058x |
|
CIMC Enric Holdings Limited
F:E8F
|
0.021x |
Annual Cash Flow Conversion Efficiency for Shanghai Medicilon Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Shanghai Medicilon Inc from 2016 to 2025. View Shanghai Medicilon Inc (688202) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥1.93 Billion ≈ $283.04 Million |
CN¥105.17 Million ≈ $15.39 Million |
0.054x | +611.58% |
| 2024-12-31 | CN¥2.14 Billion ≈ $313.17 Million |
CN¥-22.75 Million ≈ $-3.33 Million |
-0.011x | -180.10% |
| 2023-12-31 | CN¥2.51 Billion ≈ $367.41 Million |
CN¥33.32 Million ≈ $4.88 Million |
0.013x | +199.71% |
| 2022-12-31 | CN¥1.60 Billion ≈ $234.54 Million |
CN¥-21.33 Million ≈ $-3.12 Million |
-0.013x | -103.90% |
| 2021-12-31 | CN¥1.33 Billion ≈ $194.26 Million |
CN¥452.94 Million ≈ $66.28 Million |
0.341x | +86.49% |
| 2020-12-31 | CN¥1.14 Billion ≈ $166.18 Million |
CN¥207.77 Million ≈ $30.40 Million |
0.183x | +214.00% |
| 2019-12-31 | CN¥1.00 Billion ≈ $146.42 Million |
CN¥58.30 Million ≈ $8.53 Million |
0.058x | -71.49% |
| 2018-12-31 | CN¥347.89 Million ≈ $50.91 Million |
CN¥71.11 Million ≈ $10.41 Million |
0.204x | -21.38% |
| 2017-12-31 | CN¥287.32 Million ≈ $42.04 Million |
CN¥74.70 Million ≈ $10.93 Million |
0.260x | +87.44% |
| 2016-12-31 | CN¥246.09 Million ≈ $36.01 Million |
CN¥34.13 Million ≈ $4.99 Million |
0.139x | -- |
About Shanghai Medicilon Inc
Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers drug discovery, CMC development, preclinical research, biology, chemistry, catalyst screening, flow ch… Read more